Predictive factors for epidermal growth factor receptor inhibitors - The bull's-eye hits the arrow

Cancer Cell

Volumn 5, Issue 5, 2004, Pages 411-415

  Dancey, Janet E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GEFITINIB;

CANCER MORTALITY; CANCER RESEARCH; CELL PROLIFERATION; DRUG SENSITIVITY; GENE OVEREXPRESSION; HUMAN; LIGAND BINDING; LUNG NON SMALL CELL CANCER; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SHORT SURVEY; SQUAMOUS CELL CARCINOMA; SRC HOMOLOGY DOMAIN; STRUCTURAL HOMOLOGY;

EID: 2342500837     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(04)00122-9     Document Type: Review

References (30)

1. Barbone F., Bovenzi M., Cavallieri F., Stanta G. Cigarette smoking and histologic type of lung cancer in men. Chest. 112:1997;1474-1479
2. Baselga J., Rischin D., Ranson M., Calvert H., Raymond E., Kieback D.G., Kaye S.B., Gianni L., Harris A., Bjork T., et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. 20:2002;4292-4302
3. Carpenter G. The EGF receptor. a nexus for trafficking and signaling Bioessays. 22:2000;697-707
4. Cohen M.H., Williams G.A., Sridhara R., Chen G., McGuinn W.D. Jr., Morse D., Abraham S., Rahman A., Liang C., Lostritto R., et al. United States Food and Drug Administration Drug Approval summary. Gefitinib (ZD1839; Iressa) tablets Clin. Cancer Res. 10:2004;1212-1218
5. Cohen S. Nobel lecture. Epidermal growth factor. Biosci. Rep. 6:1986;1017-1028
6. Downward J., Yarden Y., Mayes E., Scrace G., Totty N., Stockwell P., Ullrich A., Schlessinger J., Waterfield M.D. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature. 307:1984;521-527
7. Ekstrand A.J., James C.D., Cavenee W.K., Seliger B., Pettersson R.F., Collins V.P. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 51:1991;2164-2172
8. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., Nishiwaki Y., Vansteenkiste J., Kudoh S., Rischin D., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 21:2003;2237-2246
9. Giaccone G., Herbst R.S., Manegold C., Scagliotti G., Rosell R., Miller V., Natale R.B., Schiller J.H., Von Pawel J., Pluzanska A., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer. A phase III trial-INTACT 1 J. Clin. Oncol. 22:2004;777-784
10. Herbst R.S., Maddox A.M., Rothenberg M.L., Small E.J., Rubin E.H., Baselga J., Rojo F., Hong W.K., Swaisland H., Averbuch S.D., et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors. results of a phase I trial J. Clin. Oncol. 20:2002;3815-3825
11. Herbst R.S., Giaccone G., Schiller J.H., Natale R.B., Miller V., Manegold C., Scagliotti G., Rosell R., Oliff I., Reeves J.A., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer. A phase III trial-INTACT 2 J. Clin. Oncol. 22:2004;785-794
12. Hirsch F.R., Varella-Garcia M., Bunn P.A. Jr., Di Maria M.V., Veve R., Bremmes R.M., Baron A.E., Zeng C., Franklin W.A. Epidermal growth factor receptor in non-small-cell lung carcinomas. Correlation between gene copy number and protein expression and impact on prognosis J. Clin. Oncol. 21:2003;3798-3807
13. Janmaat M.L., Kruyt F.A., Rodriguez J.A., Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways Clin. Cancer Res. 9:2003;2316-2326
14. Kabat G.C. Aspects of the epidemiology of lung cancer in smokers and nonsmokers in the United States. Lung Cancer. 15:1996;1-20
15. Kris M.G., Natale R.B., Herbst R.S., Lynch T.J. Jr., Prager D., Belani C.P., Schiller J.H., Kelly K., Spiridonidis H., Sandler A., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. a randomized trial JAMA. 290:2003;2149-2158
16. Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to Gefitinib. N. Engl. J. Med. Published online April 29, 2004. 10.1056/NEJMoa040938
17. Marugame T., Sobue T., Nakayama T., Suzuki T., Kuniyoshi H., Sunagawa K., Genka K., Nishizawa N., Natsukawa S., Kuwahara O., Tsubura E. Filter cigarette smoking and lung cancer risk; a hospital-based case-control study in Japan. Br. J. Cancer. 90:2004;646-651
18. Meert A.P., Martin B., Delmotte P., Berghmans T., Lafitte J.J., Mascaux C., Paesmans M., Steels E., Verdebout J.M., Sculier J.P. The role of EGF-R expression on patient survival in lung cancer. a systematic review with meta-analysis Eur. Respir. J. 20:2002;975-981
19. Miller V.A., Kris M.G., Shah N., Patel J., Azzoli C., Gomez J., Krug L.M., Pao W., Rizvi N., Pizzo B., et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J. Clin. Oncol. 22:2004;1103-1109
20. Mukohara T., Kudoh S., Matsuura K., Yamauchi S., Kimura T., Yoshimura N., Kanazawa H., Hirata K., Inoue K., Wanibuchi H., et al. Activated Akt expression has significant correlation with EGFR and TGF-alpha expressions in stage I NSCLC. Anticancer Res. 24:2004;11-17
21. Nishiwaki Y., Yano S., Tamura T., Nakagawa K., Kudoh S., Horai T., Noda K., Takata I., Watanabe K., Saka H., et al. Gan To Kagaku Ryoho. 31:2004;567-573
22. Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., et al. (2004). EGFR mutations in lung cancer: Correlation with clinical response to Gefitinib therapy. Science. Published online April 29, 2004. 10.1126/science.1099314
23. Reiter J.L., Threadgill D.W., Eley G.D., Strunk K.E., Danielsen A.J., Sinclair C.S., Pearsall R.S., Green P.J., Yee D., Lampland A.L., et al. Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms. Genomics. 71:2001;1-20
24. Rusch V., Klimstra D., Venkatraman E., Pisters P.W., Langenfeld J., Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin. Cancer Res. 3:1997;515-522
25. Schlessinger J. Signal transduction. Autoinhibition control. Science. 300:2003;750-752
26. Sorokin A. Activation of the EGF receptor by insertional mutations in its juxtamembrane regions. Oncogene. 11:1995;1531-1540
27. Stellman S.D., Takezaki T., Wang L., Chen Y., Citron M.L., Djordjevic M.V., Harlap S., Muscat J.E., Neugut A.I., Wynder E.L., et al. Smoking and lung cancer risk in American and Japanese men. An international case-control study Cancer Epidemiol. Biomarkers Prev. 10:2001;1193-1199
28. Takezaki T., Hirose K., Inoue M., Hamajima N., Yatabe Y., Mitsudomi T., Sugiura T., Kuroishi T., Tajima K. Dietary factors and lung cancer risk in Japanese. With special reference to fish consumption and adenocarcinomas Br. J. Cancer. 84:2001;1199-1206
29. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2:2001;127-137
30. Yoshimi I., Ohshima A., Ajiki W., Tsukuma H., Sobue T. A comparison of trends in the incidence rate of lung cancer by histological type in the Osaka Cancer Registry, Japan and in the Surveillance, Epidemiology and End Results Program, USA. Jpn. J. Clin. Oncol. 33:2003;98-104